Supernus Pharmaceuticals SUPN Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's other accrued liabilities?
- Supernus Pharmaceuticals (SUPN) reported other accrued liabilities of $82.97M in Q1 2026.
- How has Supernus Pharmaceuticals's other accrued liabilities changed year-over-year?
- Supernus Pharmaceuticals's other accrued liabilities increased by 1647.4% year-over-year, from $4.75M to $82.97M.
- What is the long-term trend for Supernus Pharmaceuticals's other accrued liabilities?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's other accrued liabilities has grown at a 33.3% compound annual growth rate (CAGR), from $9.08M to $38.22M.
- What does other accrued liabilities mean?
- This captures miscellaneous short-term obligations that do not fit into standard categories like accounts payable or accrued compensation. It often includes items such as customer deposits, short-term tax provisions, or other minor contractual liabilities. It provides insight into the breadth of the company's short-term financial commitments.